Financial insights of ASRT

MyFinsight

For the quarter ending 2025-09-30, ASRT made $49,459K in revenue. $11,445K in net income. Net profit margin of 23.14%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Income Statement	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Total revenues	49,459	29,222	26,488	29,204
Cost of sales	13,654	10,677	7,786	7,550
Research and development expenses	379	387	438	1,005
Selling, general and administrative expenses	16,930	16,960	21,975	16,726
Change in fair value of contingent consideration	-276	-	-	300
Amortization of intangible assets	5,594	9,233	9,233	6,671
Impairment of intangible assets	1,700	-	-	-
Restructuring charges	0	0	289	-
Total costs and expenses	37,981	37,257	39,721	32,252
Income (loss) from operations	11,478	-8,035	-13,233	-3,048
Interest expense	-	-	765	761
Loss on assertio therapeutics divestiture	0	-8,174	-	-
Other gain (loss)	-	-	-	45
Interest expense	770	768	-	-
Interest income	664	675	720	887
Other gain	26	6	-18	-
Total other (expense) income	-80	-8,261	-63	171
Net income (loss) before income taxes	11,398	-16,296	-13,296	-2,877
Income tax expense	-	100	-	-
Income tax benefit (expense)	-47	100	245	44
Net income (loss) and comprehensive income (loss)	11,445	-16,352	-13,541	-2,921

Basic net income (loss) per share (in dollars per share)	0.12	-0.17	-0.14	-0.03
Diluted net income (loss) per share (in dollars per share)	0.11	-0.17	-0.14	-0.03
Shares used in computing basic net income (loss) per share (in shares)	96,245,000	95,970,000	95,677,000	95,352,000
Shares used in computing diluted net income (loss) per share (in shares)	106,514,000	95,970,000	95,677,000	95,352,000